REG - Arecor Therapeutics - ARECOR STRENGTHENS COLLABORATION WITH PARTNER

Arecor TherapeuticsAnnouncement

14/02/2023 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230214:nRSN7899Pa&default-theme=true

RNS Number : 7899P  Arecor Therapeutics PLC  14 February 2023

Arecor Therapeutics plc

("Arecor" or the "Group")

 

ARECOR STRENGTHENS COLLABORATION WITH TOP 5 GLOBAL PHARMACEUTICAL PARTNER
THROUGH ADDITIONAL FORMULATION AGREEMENT

 

-      Eighth new technology partnership with major pharmaceutical and
biotech companies since IPO

 

Cambridge, UK, 14 February 2023: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
today announces that it has signed an additional formulation study agreement
with its top five global pharmaceutical partner, building on a collaboration
formed in 2022.

 

Under the terms of this agreement, Arecor will use its proprietary formulation
technology platform, Arestat™, to develop improved, stable, high
concentration, liquid formulations of its proprietary product. The partner
company will fund the initial development work and have the option to acquire
the rights to the new proprietary formulations and associated intellectual
property under a technology licensing model. This agreement follows the first
agreement with the partner company, announced in June 2022.

 

Sarah Howell, Chief Executive Officer of Arecor, said: "The expansion of this
important collaboration with a leading pharmaceutical company clearly
demonstrates Arecor's expertise and the adaptability of our Arestat™
platform.  This is the eighth new technology partnership with major
pharmaceutical and biotech companies since Arecor's IPO in June 2021, which
shows the need for our technology among leading pharmaceutical companies
developing innovative products.

 

"This is key to the positive impact we can bring to our partners' development
programmes, not only providing upside potential to Arecor from future
licensing opportunities, but also further cementing our reputation within the
industry as the go-to partner for challenging and complex formulation
expertise."

 

-ENDS-

 

 

For more information, please contact:

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:sarah.howell@arecor.com)

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:info@arecor.com)

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com (mailto:mo.noonan@arecor.com)

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Lindsey Neville      Tel: +44 (0) 20 3709 5700

                                                  Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRDGGDDXDBDGXX